Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia

Kris M. Mahadeo, Lucia R. Wolgast, Christine Mcmahon, Peter D. Cole

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Mastocytosis is primarily limited to the cutaneous variant in pediatric patients. Systemic mastocytosis (SM) has been associated with t(8;21) acute myeloid leukemia (AML) in adults. We provide the first report of a child with t(8;21) AML, diagnosed with asymptomatic SM following four cycles of chemotherapy. Unlike most adults with SM/AML, she was not found to have a c-KIT (D816V) mutation. SM persisted in the bone marrow after completion of chemotherapy, and her AML relapsed 9 months off-treatment. Although she achieved a second remission, mastocytosis persists in the marrow. Pediatric patients with t(8;21) AML/SM may represent a high-risk group despite favorable cytogenetics.

Original languageEnglish (US)
Pages (from-to)684-687
Number of pages4
JournalPediatric Blood and Cancer
Volume57
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Systemic Mastocytosis
Acute Myeloid Leukemia
Mastocytosis
Bone Marrow
Pediatrics
Drug Therapy
Cytogenetics
Skin
Mutation

Keywords

  • AML
  • Molecular diagnosis and therapy
  • Pediatric hematology/oncology
  • Systemic mastocytosis

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia. / Mahadeo, Kris M.; Wolgast, Lucia R.; Mcmahon, Christine; Cole, Peter D.

In: Pediatric Blood and Cancer, Vol. 57, No. 4, 10.2011, p. 684-687.

Research output: Contribution to journalArticle

Mahadeo, Kris M. ; Wolgast, Lucia R. ; Mcmahon, Christine ; Cole, Peter D. / Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia. In: Pediatric Blood and Cancer. 2011 ; Vol. 57, No. 4. pp. 684-687.
@article{0b6d1bfb8e0d4e44a8a2fef99dc53203,
title = "Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia",
abstract = "Mastocytosis is primarily limited to the cutaneous variant in pediatric patients. Systemic mastocytosis (SM) has been associated with t(8;21) acute myeloid leukemia (AML) in adults. We provide the first report of a child with t(8;21) AML, diagnosed with asymptomatic SM following four cycles of chemotherapy. Unlike most adults with SM/AML, she was not found to have a c-KIT (D816V) mutation. SM persisted in the bone marrow after completion of chemotherapy, and her AML relapsed 9 months off-treatment. Although she achieved a second remission, mastocytosis persists in the marrow. Pediatric patients with t(8;21) AML/SM may represent a high-risk group despite favorable cytogenetics.",
keywords = "AML, Molecular diagnosis and therapy, Pediatric hematology/oncology, Systemic mastocytosis",
author = "Mahadeo, {Kris M.} and Wolgast, {Lucia R.} and Christine Mcmahon and Cole, {Peter D.}",
year = "2011",
month = "10",
doi = "10.1002/pbc.23026",
language = "English (US)",
volume = "57",
pages = "684--687",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Systemic mastocytosis in a child with t(8;21) acute myeloid leukemia

AU - Mahadeo, Kris M.

AU - Wolgast, Lucia R.

AU - Mcmahon, Christine

AU - Cole, Peter D.

PY - 2011/10

Y1 - 2011/10

N2 - Mastocytosis is primarily limited to the cutaneous variant in pediatric patients. Systemic mastocytosis (SM) has been associated with t(8;21) acute myeloid leukemia (AML) in adults. We provide the first report of a child with t(8;21) AML, diagnosed with asymptomatic SM following four cycles of chemotherapy. Unlike most adults with SM/AML, she was not found to have a c-KIT (D816V) mutation. SM persisted in the bone marrow after completion of chemotherapy, and her AML relapsed 9 months off-treatment. Although she achieved a second remission, mastocytosis persists in the marrow. Pediatric patients with t(8;21) AML/SM may represent a high-risk group despite favorable cytogenetics.

AB - Mastocytosis is primarily limited to the cutaneous variant in pediatric patients. Systemic mastocytosis (SM) has been associated with t(8;21) acute myeloid leukemia (AML) in adults. We provide the first report of a child with t(8;21) AML, diagnosed with asymptomatic SM following four cycles of chemotherapy. Unlike most adults with SM/AML, she was not found to have a c-KIT (D816V) mutation. SM persisted in the bone marrow after completion of chemotherapy, and her AML relapsed 9 months off-treatment. Although she achieved a second remission, mastocytosis persists in the marrow. Pediatric patients with t(8;21) AML/SM may represent a high-risk group despite favorable cytogenetics.

KW - AML

KW - Molecular diagnosis and therapy

KW - Pediatric hematology/oncology

KW - Systemic mastocytosis

UR - http://www.scopus.com/inward/record.url?scp=79961181551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961181551&partnerID=8YFLogxK

U2 - 10.1002/pbc.23026

DO - 10.1002/pbc.23026

M3 - Article

C2 - 21671435

AN - SCOPUS:79961181551

VL - 57

SP - 684

EP - 687

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -